{"DataElement":{"publicId":"6438197","version":"1","preferredName":"Esophageal Adenocarcinoma AJCC Edition 8 Clinical Group Stage","preferredDefinition":"Clinical stage group based on the combination of T, N, and M categories and relevant prognostic factors for esophageal adenocarcinoma, using AJCC Ed. 8 criteria.","longName":"ESAD_AJC8_CLN_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6438188","version":"1","preferredName":"Esophageal Adenocarcinoma Clinical Stage Grouping","preferredDefinition":"A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus.  Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported.  Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas.  Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  The prognosis is poor._Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"6438155v1.0:2925061v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6438155","version":"1","preferredName":"Esophageal Adenocarcinoma","preferredDefinition":"A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus.  Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported.  Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas.  Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  The prognosis is poor.","longName":"C4025","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophageal Adenocarcinoma","conceptCode":"C4025","definition":"A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus.  Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported.  Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas.  Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"76A3CB4F-CA94-5DE4-E053-F662850A67B4","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2925061","version":"1","preferredName":"Clinical Stage Grouping","preferredDefinition":"Having to do with the examination and treatment of patients.:Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C25398:C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FD8E36A-281E-6D78-E040-BB89AD43144A","latestVersionIndicator":"Yes","beginDate":"2009-07-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-29","modifiedBy":"ONEDATA","dateModified":"2009-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"76A32AEC-27C0-6248-E053-F662850A8F46","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"TAYLORT","dateModified":"2018-10-04","changeDescription":"10-4-18 Changed from Draft New to Released/tmt.  9/24/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6437972","version":"1","preferredName":"Esophageal Adenocarcinoma American Joint Committee on Cancer Edition 8 Clinical Group Stage","preferredDefinition":"A term that refers to the clinical staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6437972v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IVB","valueDescription":"Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","ValueMeaning":{"publicId":"6437974","version":"1","preferredName":"Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","longName":"6437974","preferredDefinition":"Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","conceptCode":"C133410","definition":"Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76A05D91-5E34-76E9-E053-F662850A0503","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76A05D91-5E4D-76E9-E053-F662850A0503","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","ValueMeaning":{"publicId":"6437976","version":"1","preferredName":"Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","longName":"6437976","preferredDefinition":"Stage IVA includes: (T1-4a, N2, M0); (T4b, N0-2, M0); (Any T, N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","conceptCode":"C133409","definition":"Stage IVA includes: (T1-4a, N2, M0); (T4b, N0-2, M0); (Any T, N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76A05D91-5E5A-76E9-E053-F662850A0503","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76A05D91-5E73-76E9-E053-F662850A0503","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","deletedIndicator":"No"},{"value":"III","valueDescription":"Clinical Stage III Esophageal Adenocarcinoma AJCC v8","ValueMeaning":{"publicId":"6437978","version":"1","preferredName":"Clinical Stage III Esophageal Adenocarcinoma AJCC v8","longName":"6437978","preferredDefinition":"Stage III includes: (T2, N1, M0); (T3, N0-1, M0); (T4a, N0-1, M0). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Stage III Esophageal Adenocarcinoma AJCC v8","conceptCode":"C133407","definition":"Stage III includes: (T2, N1, M0); (T3, N0-1, M0); (T4a, N0-1, M0). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76A05D91-5E80-76E9-E053-F662850A0503","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76A05D91-5E99-76E9-E053-F662850A0503","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","deletedIndicator":"No"},{"value":"IIB","valueDescription":"Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8","ValueMeaning":{"publicId":"6437980","version":"1","preferredName":"Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8","longName":"6437980","preferredDefinition":"Stage IIB includes: T2, N0, M0. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8","conceptCode":"C133406","definition":"Stage IIB includes: T2, N0, M0. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76A05D91-5EA6-76E9-E053-F662850A0503","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76A05D91-5EBF-76E9-E053-F662850A0503","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","deletedIndicator":"No"},{"value":"IIA","valueDescription":"Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","ValueMeaning":{"publicId":"6437982","version":"1","preferredName":"Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","longName":"6437982","preferredDefinition":"Stage IIA includes: T1, N1, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","conceptCode":"C133405","definition":"Stage IIA includes: T1, N1, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76A05D91-5ECC-76E9-E053-F662850A0503","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76A05D91-5EE5-76E9-E053-F662850A0503","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","deletedIndicator":"No"},{"value":"I","valueDescription":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8","ValueMeaning":{"publicId":"6437984","version":"1","preferredName":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8","longName":"6437984","preferredDefinition":"Stage I includes: T1, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8","conceptCode":"C133403","definition":"Stage I includes: T1, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76A05D91-5EF2-76E9-E053-F662850A0503","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76A05D91-5F0B-76E9-E053-F662850A0503","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","deletedIndicator":"No"},{"value":"II","valueDescription":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8","ValueMeaning":{"publicId":"6437986","version":"1","preferredName":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8","longName":"6437986","preferredDefinition":"Stage II includes: IIA: T1, N1, M0; IIB: T2, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8","conceptCode":"C133404","definition":"Stage II includes: IIA: T1, N1, M0; IIB: T2, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76A05D91-5F18-76E9-E053-F662850A0503","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76A05D91-5F31-76E9-E053-F662850A0503","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","deletedIndicator":"No"},{"value":"0","valueDescription":"Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8","ValueMeaning":{"publicId":"6437988","version":"1","preferredName":"Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8","longName":"6437988","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8","conceptCode":"C133402","definition":"Stage 0 includes: Tis, N0, M0. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76A05D91-5F3E-76E9-E053-F662850A0503","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76A05D91-5F57-76E9-E053-F662850A0503","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6437971","version":"1","preferredName":"Esophageal Adenocarcinoma by AJCC v8 Clinical Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the clinical staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C133401:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophageal Adenocarcinoma by AJCC v8 Clinical Stage","conceptCode":"C133401","definition":"A term that refers to the clinical staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76A05D91-5E07-76E9-E053-F662850A0503","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"76A05D91-5E18-76E9-E053-F662850A0503","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"TAYLORT","dateModified":"2018-10-04","changeDescription":"10-4-18 Changed from Draft New to Released/tmt. Content reviewed and approved by requesting organization.  9/24/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6437866","version":"1","longName":"Esophagus and Esophagogastric Junction","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Clinical disease stage","type":"Preferred Question Text","description":"Clinical disease stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"76A4045F-27DB-42A2-E053-F662850AA860","latestVersionIndicator":"Yes","beginDate":"2018-09-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-09-24","modifiedBy":"TAYLORT","dateModified":"2018-10-04","changeDescription":"10-4-18 Changed from Draft New to Released/tmt. Content reviewed and approved by requesting organization. 9-24-18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}